Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCB-313 in peritoneal malignancies
NCT03443674Phase 1Completed
- Sponsor
- Clover Biopharmaceuticals
- Start
- Jun 2018
- Primary completion
- May 2021
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rilunermin alfa in peritoneal malignancies (PSM), sponsored by Clover Biopharmaceuticals. Primary endpoint: Occurrence of serious adverse events (SAEs) and/or TEAEs at 41 days. Started Jun 2018; status: completed.
02
Drugs
rilunermin alfa
03
Conditions
peritoneal malignancies (PSM)
Beyond the preview
Go deeper on NCT03443674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03443674.